Achillion Strengthens Clinical Team, Readies HCV Nuc For Clinical Development
This article was originally published in The Pink Sheet Daily
CSO Milind Deshpande will succeed Michael Kishbauch as CEO, while two HCV veterans from other companies will strengthen Achillion’s clinical development team. Meanwhile, the virology firm expects to file an IND for a nucleoside polymerase inhibitor later this year; only two antivirals from that class currently are in clinical development in HCV.
You may also be interested in...
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.
Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.